Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 7/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511934 | 0.92 | CXCR3 (0.40) | NPC1HPGDRAB9ASMN1; SMN2F10 | |
| SCHEMBL13674553 | 0.92 | CXCR3 (0.40) | NPC1HPGDRAB9ASMN1; SMN2F10 | |
| SCHEMBL13675515 | 0.84 | MAPT (0.41) | RAB9ASMN1; SMN2FFAR4POLB | |
| SCHEMBL13675471 | 0.84 | SLC6A9 (0.42) | SMN1; SMN2FFAR4 | |
| SCHEMBL5547214 | 0.84 | CXCR3 (0.42) | NPC1F10CXCR3POLB | |
| SCHEMBL13674555 | 0.84 | CXCR3 (0.42) | NPC1F10CXCR3POLB | |
| SCHEMBL4501678 | 0.83 | FFAR4 (0.36) | FFAR4CXCR3 | |
| SCHEMBL13675470 | 0.82 | FFAR4 (0.36) | HPGDFFAR4 | |
| SCHEMBL4519486 | 0.81 | KLKB1 (0.36) | NPC1HPGDRAB9ASMN1; SMN2CXCR3 | |
| SCHEMBL13674551 | 0.78 | PDK2 (0.42) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | NPC1 286/4885HPGD 63/4885RAB9A 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.